Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions

Journal of Oral Pathology and Medicine

Volumn 25, Issue 5, 1996, Pages 232-238

  Matsuda, H ^a   Konishi, N ^a   Hiasa, Y ^a   Hayashi, I ^a   Tsuzuki, T ^a   Tao, M ^a   Kitahori, Y ^a   Yoshioka, N ^a   Kirita, T ^a   Sugimura, M ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Oral carcinomas; p16 CDKN2; p53; ras

Indexed keywords

CARRIER PROTEIN; DIAGNOSTIC AGENT; ENZYME INHIBITOR; PRIMER DNA; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P16INK4A;

ARTICLE; EPITHELIUM; EXON; GENE DELETION; GENETICS; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MOUTH TUMOR; MUTATION; ONCOGENE RAS; PATHOLOGY; POLYMERASE CHAIN REACTION; PRECANCER; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PRIMERS; ENZYME INHIBITORS; EPITHELIUM; EXONS; GENE DELETION; GENES, P53; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MOUTH NEOPLASMS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PRECANCEROUS CONDITIONS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 0030135324     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.1996.tb01377.x     Document Type: Article

References (56)

1. SERRANO N, HANNON G, BEACH D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7.
2. KAMB A, GRUIS N, FEEDHAUS J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-9.
3. NOBORI T, MIURA K, WU D, LOTS A, TAKAHASHI K, CARSON D. Deletions of the cyclin- dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6.
4. NIGRO JM, BAKER SJ, PRESSINGER AC, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705-8.
5. CASSON AG, MUKHOPADHAY T, CLEARY KR, RO JY, LEVIN B, ROTH A. p53 gene mutation in Barrett's epithelium and esophageal cancer. Cancer Res 1991; 51: 4495-9.
6. TAKAHASI T, SUZUKI H, HIDA T, SEKIDO Y, ARITOSHI Y, UEDA R. The p53 gene is very frequently mutated in small cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991; 6: 1775-8.
7. WARNAKUEASURTYA KAAS, CHANG SE, JOHNSON NW. Point mutations in the Haras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinomas, but are infrequent in British cases. J Oral Pathol Med 1992; 21: 225-9.
8. YEUDAEE WA, TORRANCE LK, EESEGOOD KA, SPETGHT P, SCUEEY C, PRIME SS. Ras gene point mutation is a rare event in premalignant tissues and malignant cells and tissues from oral mucosal lesions. Eur J Cancer 1993, 29B: 63-7.
9. LANE DP. p53, guardian of the genome. Nature 1992; 358: 15-6.
10. HARTWELL L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992; 71: 543-6.
11. KAWASAKI Y, MONDEN T, MORIMOTO H, et al. Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol 1992; 97: 244-9.
12. MAZARS R, PUJOE P, MAUDELONDE T, JEANTEUR P, THEILLET C. p53 mutations in ovarian cancer: a late event? Oncogene 1991; 6: 1685-90.
13. ITO T, SEYAMA T, NAKAMURA N, AKIYAMA M. Unique association of p53 mutations with undifferentiated tumors but not with carcinomas of the thyroid gland. Cancer Res 1992; 52: 1369-71.
14. SHIN DM, KIM J, RO JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54: 321-6.
15. BOS JL. ras oncogenes in human cancer A review. Cancer Res 1989; 49: 4682-9.
16. GIBBS JB, SIGAE IS, POE M, SCOENICK EM. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci USA 1984; 81: 5704-8.
17. SEAUGHYER DP, SOUTHWICH HW, SMEIKAE W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
18. INCZE J, VAUGHAN CW, LUI P, STRONG MS, KUEAPADITHAROM B. Premalignant changes in normal appearing epithelium in patients with squamous carcinomas of the upper aerodigestive tract. Am J Surg 1982; 144: 401-5.
19. RABINOVITCH PS, REID BJ, HAGGITT RC, NORWOOD TH, RUBIN CE. Progression to cancer in Barrett's esophagus is associated with enomic instability. Lab Invest 1988; 60: 65-71.
20. SIEVERMAN S, GORSKY M, LOZADA F. Oral leukoplakia and malignant transformation: a follow up of 257 patients. Cancer 1984; 53: 63-8
21. WEINBERG RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989; 49: 3713-21
22. HUSSUSSIAN CJ, STRUEWING JP, GOEDSTETN AM, et al. Germline p16 mutations in familial melanoma. Nature Genetics 1994; 8: 15-21
23. LEHMAN TA, BENNETTO WP, METCAEF RA, et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991; 51: 4090-96.
24. SUZUKI Y, ORITA M, SHIRAISHI M, HAYASHI K, SEKIYA T. Detection of ras gene mutations in human lung cancers by single - strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990; 5: 1037-43
25. ORITA M, IWAHANA H, KANAZAWA H, HAYASHI K, SEKIYA T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphism. Proc Natl Acad Sci USA 1989; 86: 2766-70.
26. ZHANG SE, KEETN-SZANTO AJP, SAUTER ER, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994; 54: 5050-3
27. AH-SEE KW, COOKE TG, PICKFORD IR, SOUTAR D, BALMAIN A. An allelotype of squamous carcinoma of the head and neck using microsatellite markers. Cancer Res 1994; 54: 1617-11.
28. NAWROZ H, VAN DER RIET P, HRUBAN RH, KOCH W, RUPPERT JM, SIDRANSKY D. Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994; 54: 1152-5.
29. VAN DER RIET P, NAWROZ H, HRUBAN RH, et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994; 54: 1156-8.
30. NEVIEEE EM, STEWART M, MYSKOW M, DONNEEEY RJ, FTEED JK. Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. Oncogene 1995; 11: 581-5.
31. ZHANG SY, KEEIN-SZANTO AJP, SAUTER ER, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994; 54: 5050-3.
32. SUN Y, HIEDESHEIM A, LANIER AEP, et al. No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene 1995; 10: 785-8.
33. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995; 55: 1448-1.
34. MORI T, MIURA K, AOKI T, NISHIHIRA T, MORIS, NAKAMURA Y. Frequent somatic mutation of the MTS 1/CDKN2 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994; 54: 3396-7.
35. LO KW, HUANG DP, LAU KM. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 1995; 55: 2039-43.
36. NISHIOKA H, HIASA Y, HAYASHI I, KITAHORI Y, KONISHI N, SUGIMURA M. Immunohistochemical detection of p53 oncoprotein in human oral squamous cell carcinomas and leukoplakias: Comparison with proliferating cell nuclear antigen staining and correlation with clinicopathological findings. Oncology 1993; 50: 426-9.
37. NEES M, HOMANN N, DISCHER H, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: A possible molecular basis for the development of multiple tumors. Cancer Res 1993; 53: 4189-96.
38. OGDEN GR, KIDDIE RA, LUNNY DP, LANE DP. Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. J Pathol 1992; 166: 389-94.
39. SARANATH D, CHANG SE, BHOITE LT, et al. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 1991; 63: 573-8.
40. RUMSBY G, CARTER RL, GUSTERSON BA. Low incidence of ras oncogene activation in human squamous cell carcinoma. Br J Cancer 1990; 61: 365-8.
41. KIARIS H, SPANDIDOS DA, JONES AS, VAUGHAN ED, FIEED JK. Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer 1995; 72: 123-8.
42. FIEED JK, SPANDTDOS DA, MAEEIRI A, GOSNEY JR, YIAGNISIS M, STEEE PM. Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 1991; 64: 573-7.
43. BRENNAN JA, BOYEE JO, KOCH WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous - cell carcinoma of the head and neck. N Engl J Med 1995; 332: 712-7.
44. HARRIS CC, HOLLSTEIN M. Clinical implications of p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-27.
45. MOLL UM, RIOU G, LEVINE AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992; 89: 7262-6.
46. ZIEGLER A, LEFFELL OJ, KUNAEA S, et al. Mutational hotspots due to sun light in the p53 gene of nonmelanoma skin cancer. Proc Natl Acad Sci USA 1993; 90: 4216-20.
47. GUPTA RK, PATEL K, BOOMER WF, BODMER JG. Mutation of p53 in primary biopsy material and cell lines from Hodgkin's disease. Proc Natl Acad Sci USA 1993; 90: 2817-21.
48. SOINT Y, VAHAKANGAS K, NUORVA K, KAMEE D, LANE DP, PAKKO P. p53 immunohistochemistry in malignant fibrous histiocytomas and other esenchymal tumors. J Pathol 1992; 168: 29-33.
49. MATSUSHTMA A, GESARMAN E, CHADBURN A, KNOWLES DM. Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 1994; 144: 573-84.
50. SCHENKMAN NS, SESTERHENN IA, WASHINGTON L, et al. Increased p53 protein does not correlate to p53 gene mutations in microdissected human esticular germ cell tumors. J Urol 1995; 154: 617-21.
51. KONISHI N, HIASA Y, HAYASHI I, et al. p53 mutations occur in clinical, but not latent, human prostate carcinoma. Jpn J Cancer Res 1995; 86: 57-63.
52. SUZUKI T, SHTDARA K, HARA F, NAKAJIMA T. High frequency of p53 abnormality in laryngeal cancers of heavy smokers and its relation to human papillomavirus infection. Jpn J Cancer Res 1994; 85: 1087-93.
53. BENNETT WP, HOEESTEIN MC, METCAEF RA, et al. P53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992; 52: 6090-7.
54. KONISHIN, HIASA Y, MATSUDA H, et al. Intratumor cellular heterogeneity and alterations in ras oncogene and P53 tumor suppressor gene in human prostate carcinoma. Am J Pathol (in press).
55. HAYASHI I, KONISHI N, MATSUDA H, et al. Comparative analysis of P16/CDKN2, P53 and ras gene alterations in human non-small cell lung ancers, with and without associated pulmonary asbestosis. Int J Oncology (in press)
56. GUSTERSON BA, ANBAZHAGAN R, WARREN W, et al. Expression of P53 in premalignant and malignant squamous epithelium. Oncogene 1991; 4: 1785-9.